What Valar Labs does

Valar Labs is a venture-backed precision oncology company founded in 2021 and headquartered in Palo Alto, California, that builds AI-powered diagnostic tests which analyze routine H&E-stained tumor pathology slides to predict cancer treatment response and stratify risk. Its proprietary Computational Histology Artificial Intelligence (CHAI) platform is trained on more than 500,000 expert pathologist annotations across thousands of patients and operates on local compute infrastructure rather than the cloud. The company ships three commercial products through a branded portfolio architecture: Vesta (genitourinary), comprising Vesta Bladder BCGPredict and Vesta Bladder Risk Stratify for non-muscle invasive bladder cancer, and Vesta Prostate Risk Stratify for metastatic hormone-sensitive prostate cancer; and Vitara (gastrointestinal), anchored by Vitara Pancreas ChemoPredict for first-line chemotherapy selection in advanced pancreatic adenocarcinoma.

Valar Labs monetizes primarily by performing diagnostic tests in its own CLIA-certified laboratory and billing patients and insurers per test, with a Financial Access Program for patients with financial needs, while also generating revenue through professional services partnerships with pharmaceutical companies for biomarker discovery, diagnostic co-development, and automated screening for clinical trial enrollment. Commercial reach is built on a hybrid distribution model combining direct sales to licensed physicians (via the portal.valarlabs.com online portal and a growing urology field sales team) with national laboratory network distribution partnerships, most recently PathNet Lab and Acupath (both December 2025). The customer base spans urologic oncologists treating NMIBC, medical oncologists managing mHSPC and advanced pancreatic cancer, and unnamed leading pharmaceutical companies.

The company is small (11-50 employees, with engineering deliberately capped at seven people who own the full stack from glass slide to clinical report) and has raised approximately $26 million in venture funding, including a $4 million seed round in April 2022 and a $22 million Series A in May 2024 co-led by DCVC and Andreessen Horowitz (a16z) with participation from Pear VC. Validation is anchored in peer-reviewed publications across Journal of Clinical Oncology, European Urology, Journal of Urology, European Urology Oncology, and Cell Reports Medicine, with clinical advisors drawn from Stanford, UTMB, Fred Hutch Cancer Center, Cedars Sinai, and UTSW.

Name

Valar Labs

Legal name

Valar Labs

Website

https://valarlabs.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Valar Labs is a Palo Alto-based precision oncology company that uses AI to analyze routine H&E pathology slides and predict cancer treatment response, offering Vesta Bladder, Vesta Prostate, and Vitara Pancreas diagnostics to urologists, oncologists, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

AI Cancer Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

Keywords

• AI cancer diagnostics
• Computational pathology
• Cancer treatment response prediction
• Predictive biomarker testing
• Digital pathology AI

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Diagnostic Test Sales (CLIA-Certified Laboratory): Revenue from per-test fees for Vesta Bladder, Vesta Prostate, and Vitara Pancreas tests performed in Valar Labs' own CLIA-certified laboratory. Tests are ordered by licensed physicians, billed to patients and insurers, and Valar Labs offers a Financial Access Program supporting patients with financial needs. Tests are delivered within 2-3 days of sample receipt.
2. Pharmaceutical R&D Partnerships: Revenue from partnering with leading pharmaceutical companies to deploy Valar's AI algorithms for advancing R&D programs. Includes biomarker discovery for therapy response prediction, diagnostic development, and automated screening for molecular biomarkers to increase clinical trial enrollment and lower costs.
3. Laboratory Network Distribution Partnerships: Revenue from partnerships with national laboratory networks (PathNet Lab, Acupath) that distribute Vesta AI-powered bladder cancer diagnostics across the United States, expanding clinical access to non-muscle invasive bladder cancer (NMIBC) testing.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Valar Labs builds AI-powered diagnostic tests (Vesta and Vitara portfolios) that analyze routine H&E-stained tumor pathology slides to predict patient-specific treatment response and stratify risk in bladder, prostate, and pancreatic cancers. Diagnostics are processed in the company's CLIA-certified laboratory and delivered to licensed physicians in 2-3 days. The company also partners with pharmaceutical companies to deploy its AI algorithms for biomarker discovery, diagnostic development, and clinical trial screening automation.

Product overview

Valar Labs operates a platform-plus-modules architecture: a single underlying AI platform (CHAI - Computational Histology Artificial Intelligence) powers two distinct branded product portfolios. Vesta is the genitourinary-focused portfolio comprising Vesta Bladder BCGPredict (BCG response prediction for NMIBC), Vesta Bladder Risk Stratify (recurrence/progression risk in NMIBC), and Vesta Prostate Risk Stratify (Favorable vs Unfavorable risk classification for mHSPC triplet therapy selection). Vitara is the gastrointestinal-focused portfolio comprising Vitara Pancreas ChemoPredict (G-Preference vs F-Preference first-line chemotherapy selection for advanced pancreatic adenocarcinoma). All products use the same workflow: receive an existing digitized H&E pathology slide, return a structured AI-generated biomarker report in 2-3 days via Valar Labs' CLIA-certified laboratory and secure online portal, with no additional biopsy required.

Differentiator

Problem solved

Functional benefit

Brands

• Vesta: Valar Labs' genitourinary-focused portfolio of AI-powered pathology tests, including Vesta Bladder (Risk Stratify, BCGPredict) and Vesta Prostate Risk Stratify, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.
• Vitara

Products and services

• Vesta Bladder BCGPredict AI pathology diagnostic test for non-muscle invasive bladder cancer (NMIBC) that predicts patient response to intravesical BCG therapy using routine H&E histology slides; biomarker-present patients have a 2x elevated risk of non-response to BCG and demonstrated higher likelihood of success with alternative therapy. Validated in over 1,000 NMIBC patients across an international 12-center cohort. Ordered by licensed physicians.
• Vesta Bladder Risk Stratify Prognostic AI test for non-muscle invasive bladder cancer that delivers individualized risk scores for high-grade recurrence and muscle-invasive disease progression. Patients with high recurrence scores have a 2x elevated risk of high-grade recurrence over 24 months; high progression score patients have an almost 4x elevated risk of progression within 3 years. Outperforms existing EAU and AUA stratification frameworks.
• Vesta Prostate Risk Stratify AI pathology test for metastatic hormone-sensitive prostate cancer (mHSPC) that classifies patients as Favorable or Unfavorable Risk to predict benefit of triplet therapy (ADT + ARPi + docetaxel) versus doublet therapy. Developed using data from ENZAMET and CHAARTED phase 3 trials in over 1,000 patients; results returned in 2-3 days from a single H&E slide from prostate, lymph node, or bone tissue.
• Vitara Pancreas ChemoPredict AI pathology test for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that classifies tumors as G-Preference (Gemcitabine/Nab-Paclitaxel) or F-Preference (FOLFIRINOX) based on histologic features, enabling biomarker-matched first-line chemotherapy selection. Developed and validated across over 50 centers including multiple prospective studies; patients with biomarker-aligned regimens showed superior progression-free and overall survival.
• Pharmaceutical R&D AI Partnership Services Partnerships with leading pharmaceutical companies in which Valar Labs deploys its CHAI AI algorithms to advance R&D programs, including biomarker discovery for therapy response prediction, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase clinical trial enrollment and lower costs.

Quantifiable outcome

• Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients (Vesta Bladder BCGPredict).
• +6 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• PathNet LabcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Strategic partnership announced December 22, 2025 to provide AI-powered bladder cancer diagnostics across the United States. The collaboration aims to enhance personalized care and clinical decision-making in non-muscle invasive bladder cancer (NMIBC) by delivering Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network.
• AcupathcoreChannel Partner/ Reseller/ Distributor · 3 December 2025Strategic partnership announced December 3, 2025 to deliver Vesta AI-powered diagnostic tests for non-muscle invasive bladder cancer through Acupath's pathology laboratory services.
• PathNet LabcoreChannel Partner/ Reseller/ DistributorStrategic partnership announced December 22, 2025 to deliver Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network. Combines Valar Labs' computational pathology capabilities with PathNet's established lab infrastructure to expand adoption of AI-powered bladder cancer diagnostics nationwide for non-muscle invasive bladder cancer (NMIBC) management.
• AcupathcoreChannel Partner/ Reseller/ DistributorStrategic partnership announced December 3, 2025 to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The collaboration leverages Acupath's pathology laboratory services to make Vesta accessible to clinicians managing NMIBC.
• Pancreatic Cancer Action Network (PanCAN)coreStrategic or Co-development PartnerProvided data through PanCAN's Know Your Tumor initiative, which was used in Valar Labs' pivotal Journal of Clinical Oncology study validating the Vitara Pancreas ChemoPredict AI diagnostic. The COMPASS clinical trial data was also used in the validation study.
• Leading pharmaceutical companies (unnamed)coreStrategic or Co-development PartnerValar Labs partners with leading pharmaceutical companies, deploying AI algorithms to advance R&D programs. Includes biomarker discovery for therapy response, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase trial enrollment and lower costs. Specific pharma partners are not named publicly.
• Stanford Health CareminorStrategic or Co-development PartnerJay Shah, MD (Urologist, Chief of Medical Staff for Stanford Health Care) serves as scientific advisor and user of Vesta, providing clinical testimonials and feedback on Vesta Bladder BCGPredict integration.
• University of Texas Medical Branch (UTMB)minorStrategic or Co-development PartnerStephen B. Williams, MD (Associate Chief Medical Officer, Chief of Urology, Director of Urologic Oncology at UTMB) is a scientific advisor and active user of Vesta Bladder, providing clinical validation and testimonials.
• Fred Hutch Cancer CenterminorStrategic or Co-development PartnerEric Collisson, MD (oncologist and professor at Fred Hutch Cancer Center) serves as a scientific advisor to Valar Labs and has provided public testimonials about Vesta's clinical impact.
• Cedars Sinai Medical CenterminorStrategic or Co-development PartnerAndrew Hendifar, MD (Medical Oncologist and Medical Director of Pancreatic Cancer at Cedars Sinai) serves as a scientific advisor to Valar Labs; lead author of the pivotal Journal of Clinical Oncology study validating Vitara Pancreas ChemoPredict (Hendifar/Knox et al., Feb 2026).
• UT Southwestern (UTSW)minorStrategic or Co-development PartnerYair Lotan, MD (Chief of Urologic Oncology and Vice Chair of Urology at UTSW) serves as a scientific advisor to Valar Labs; co-author on multiple Vesta Bladder validation studies published in Journal of Urology and European Urology.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Artera (formerly ArteraAI): Artera develops AI-driven prognostic and predictive biomarkers in oncology, with a leading prostate cancer test that personalizes treatment decisions — directly overlapping with Valar Labs' Vesta Prostate Risk Stratify for mHSPC triplet-therapy selection. Both companies build H&E-based AI biomarkers validated in prospective randomized phase 3 trials and commercialize through pathology channels.
• PathAI: PathAI is a leading computational pathology AI company building diagnostic and biomarker products across multiple cancer types, including partnerships with pharma for biomarker development. It overlaps with Valar's CHAI platform in applying deep learning to H&E slides for oncology applications and competes for the same pharma R&D and pathology channel relationships.
• Paige.AI: Paige builds AI applications for pathology, with FDA-authorized products for prostate cancer detection. Its H&E-based AI diagnostics compete directly with Valar's Vesta Prostate Risk Stratify in the urologic oncology workflow, and Paige offers an established commercial footprint in pathology labs.
• Owkin: Owkin applies AI to pathology and clinical data for biomarker discovery and oncology diagnostics, with a strong biopharma R&D partnership model. It directly mirrors Valar's positioning around AI biomarkers built from histology and deployed across pharma and clinical channels.

Broad incumbents

• Tempus Labs: Tempus is a major precision oncology diagnostics and data company offering molecular profiling, multimodal AI, and clinical decision support across many cancer types. While broader and primarily molecular-based, Tempus is a broad incumbent in oncology AI diagnostics and competes for the same oncologist budgets, pharma partnerships, and guideline-level positioning.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) is an established leader in oncology molecular diagnostics used by oncologists to guide therapy selection. It is a broad incumbent in the personalized cancer treatment space that Valar targets, with deep payer coverage and a large sales force in oncology.
• Caris Life Sciences: Caris offers molecular profiling and AI-driven precision oncology diagnostics across many tumor types, with a substantial biopharma partnership business. It is a broad incumbent in personalized oncology treatment selection that overlaps with Valar's positioning in AI-guided cancer therapy decisions.

Emerging players

• Strata Oncology: Strata Oncology provides precision oncology diagnostics and a clinical trial screening platform aimed at matching cancer patients to targeted therapies. It overlaps with Valar's pharma R&D offering around biomarker-driven trial enrollment and shares a focus on AI-enabled treatment selection in oncology.
• Lunit: Lunit develops AI-powered pathology and radiology products for cancer detection and treatment response prediction, including biomarkers validated in clinical studies. It is a credible emerging competitor in computational pathology AI that competes with Valar for global oncology diagnostics opportunities.
• Ibex Medical Analytics: Ibex builds AI-based pathology diagnostics deployed across multiple cancer types in clinical labs worldwide. It is an emerging player in H&E-based oncology AI that competes with Valar in the pathology channel for diagnostic-grade products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/valarlabs

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valar Labs